PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
September 18, 2025

Shorter vs. Standard Duration of Dual Antiplatelet Therapy in Acute Coronary Syndrome: A Systematic Review and Meta-Analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

MCMariana Ferreira CarvalhoCGCarolina GonçalvesAVAdriana Vazão

Discussion

Loading...

Member takes

Overview

Systematic review shows shorter dual antiplatelet therapy reduces bleeding risk in ACS patients, suggesting optimal strategies are needed.

Key Points

  • Short-duration dual antiplatelet therapy significantly reduces bleeding risk without increasing ischemic events.
  • Based on eight high-quality trials involving nearly 28,980 patients, the results indicate clear benefits for high-risk patients.
  • Meta-analysis revealed a significant reduction in stroke and mortality risk with shorter therapy duration.
  • Findings imply a need for tailored approaches to dual antiplatelet therapy in clinical practice for safer outcomes.

Cite This Study

Carvalho et al. (2025) studied this question.

synapsesocial.com/papers/68d433a3713b0b5dfea72d39https://doi.org/10.21203/rs.3.rs-7557695/v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Short- Versus Standard-Duration Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Acute Coronary Syndrome: A Systematic Review and Meta-Analysis2026
  2. 2Sequential administration of abbreviated (up to one month) dual antiplatelet therapy and Ticagrelor monotherapy versus standard dual antiplatelet therapy after percutaneous coronary intervention: A meta-analysis2025
  3. 3One‐Year Outcomes of Short‐Term Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Drug‐Eluting Stents: A Meta‐Analysis of Randomized Clinical Trials2025
  4. 4Baseline Anemia and Short Dual Antiplatelet Therapy in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention.2026
  5. 5Personalized Antithrombotic Therapy After Percutaneous Coronary Intervention: A Systematic Review of Risk‐Stratified Approaches2026